Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 26Specimen Handling 20130-nm albumin-bound paclitaxel 18Magnetic Resonance Spectroscopy 13Irinotecan 13Biopsy 12Fluorouracil 11Leucovorin 10Oxaliplatin 9Cyclophosphamide 8pembrolizumab 7fludarabine 7Albumin-Bound Paclitaxel 7Cisplatin 6Cetuximab 6Nivolumab 5durvalumab 4Taxes 4Radiosurgery 4Pemetrexed 4Capecitabine 4zimberelimab 3trastuzumab deruxtecan 3olaparib 3irinotecan sucrosofate 3dehydroftorafur 3aldesleukin 3Radiotherapy 3Immunoglobulin G 3Exercise 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × guadecitabine × 30 days × Clear all
NCT03257761 2026-06-01

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

University of Southern California

Phase 1 Active not recruiting
55 enrolled
Gastrointestinal

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡